AASUR in High Risk Prostate Cancer

NCT02772588 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: ARN-509
DRUG: Abiraterone
DRUG: Leuprolide
RADIATION: stereotactic, ultra-fractionated radiotherapy

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]